RxDoctor Payments Data

Mohamed Abdalla, MD

Internal Medicine · Astoria, NYNPI 1124037346

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 50 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$342
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$227
  • Merck$120
  • Steris Corporation$102
  • Amgen$72
  • Amarin Pharma, Inc.$59
  • plus $159 from 6 others

What the payments were for

  • Food & beverage$1,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,081 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$12,365
Medicare patients
22
Services billed
231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate79$153,760
OzempicSemaglutide123$126,471
JanumetSitagliptin Phos/Metformin Hcl118$86,200
Diclofenac Sodium75$74,941
EliquisApixaban47$27,950
JardianceEmpagliflozin46$27,266
VascepaIcosapent Ethyl112$26,292
TrulicityDulaglutide18$24,255
JanuviaSitagliptin Phosphate35$23,613
Metformin Er GastricMetformin Hcl47$20,450
Cinacalcet Hcl28$17,700
MounjaroTirzepatide13$14,704
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$13,950
FarxigaDapagliflozin Propanediol14$8,683
MyrbetriqMirabegron13$6,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$342$126,471123 claims
MerckJanumet, Januvia$120$109,813153 claims
Lilly USA, LLCTrulicity, Mounjaro$42$38,95931 claims
PfizerEliquis$19$27,95047 claims
Astellas Pharma US IncMyrbetriq$26$6,30513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Astoria

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →